ETO activators refer to a class of chemical compounds designed to modulate the activity of the ETO protein, also known as RUNX1T1 or MTG8. ETO is a part of the family of transcriptional corepressors and is known for its roles in various cellular processes including hematopoiesis and cellular differentiation. These activators typically aim to enhance or stabilize the natural function of ETO, ensuring that it remains in an active state, able to bind and influence its target genes or proteins. Such chemical modulation could be achieved through direct interaction with the ETO protein or by interfering with other proteins or molecules that regulate ETO's activity.
The mechanisms through which ETO activators function can be varied. Some might bind directly to ETO, altering its conformation to favor its active state. Others might interfere with molecules that keep ETO in its inactive form, thereby indirectly increasing its activity. Yet another subset might enhance post-translational modifications of ETO, such as phosphorylation, that are associated with its active state. The specificity and efficacy of ETO activators would be influenced by their molecular structure and the dynamics of their interaction with ETO or associated molecules. Given the intricacy of cellular signaling and protein interactions, understanding the precise mode of action of ETO activators is crucial. It offers insights into cellular mechanisms and provides a foundation for further exploration into the modulation of corepressors and other associated cellular pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, also known as Suberoylanilide Hydroxamic Acid (SAHA), is a histone deacetylase inhibitor (HDACi). It increases the acetylation of histones, which can lead to a more open chromatin structure, potentially influencing the transcriptional activity of proteins, such as ETO. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, prevents the degradation of ubiquitinated proteins. If ETO or its associated proteins are targeted for degradation via the ubiquitin-proteasome pathway, bortezomib could stabilize and indirectly increase ETO's activity by maintaining its protein levels. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, specifically targeting BCR-ABL, c-KIT, and PDGFR. While primarily known for its role in treating chronic myeloid leukemia (CML) due to BCR-ABL fusion, the impact on ETO would be more indirect. | ||||||